Scientists have found a new way to stop cancer growth without damaging healthy cells. Researchers from the Francis Crick Institute and Vividion Therapeutics discovered a compound that blocks the ...
Researchers at the Francis Crick Institute and Vividion Therapeutics have identified chemical compounds that can precisely ...
An update from Verastem ( ($VSTM) ) is now available. On October 19, 2025, Verastem announced updated data from a Phase 1/2 study of VS-7375, ...
A tissue section from a mouse model of lung metastasis showing cancer cells (green) that have attracted and activated fibroblasts (red) to support the growth of a metastatic tumor. Image: Massagué Lab ...
When it comes to cancer metastasis, it takes two to tango. That was one of the key findings of a new study led by researchers at Memorial Sloan Kettering Cancer Center (MSK): The TGF-beta and RAS ...
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK-pathway-driven cancers, today announced positive, updated efficacy and ...
Pancreatic ductal adenocarcinoma (PDAC) is characterized clinically by poor survival and mechanistically by KRAS- and autophagy-dependent growth. We and others previously demonstrated that inhibition ...
Business combination transaction with Helix Acquisition Corp. II, a special purpose acquisition company sponsored by affiliates of Cormorant Asset Management, completed on August 11, 2025 Closed ...
Promising preliminary monotherapy data for ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601 in advanced solid tumors, which had favorable safety, tolerability, and efficacy profiles that support ...
BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on ...